Kythera Biopharmaceuticals Inc's ROA from the second quarter of 2015 to the second quarter of 2014 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kythera Biopharmaceuticals Inc's ROA in the second quarter of 2015?
Kythera Biopharmaceuticals Inc recorded a cumulative net loss of $-113 million during 12 months ending in the second quarter of 2015, resulting in a negative return on assets (ROA) of -70.87%.

However, within the Healthcare sector 500 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2015 quarter, so far to 4925, from total ROA ranking in the first quarter of 2015 at 4951.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2015) II. Quarter	(Mar 31 2015) I. Quarter	(Dec 31 2014) IV. Quarter	(Sep 30 2014) III. Quarter	(Jun 30 2014) II. Quarter
Y / Y Total Assets Change	40.85 %	38.33 %	-40.36 %	88.3 %	81.66 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-113	-95	-136	-125	-114
Return On Assets (TTM)	-70.87 %	-65.6 %	-104.41 %	-85.09 %	-85.98 %
KYTH's Total Ranking	# 4925	# 4951	# 5305	# 4942	# 4910
Total Assets (TTM) in million	195	215	103	122	139
Seq. Total Assets Change	-9.22 %	108.17 %	-15.04 %	-12.27 %	-10.85 %
Seq. Net Income Change	-	-	-	-	-

KYTH's 5 Years Annual ROA >> Back to KYTH Management Effectiveness >> Compare KYTH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 221
Sector	# 501
Overall	# 4009

Return On Assets Statistics
High	Average	Low
-51.5 %	-78.02 %	-104.41 %
(Dec 31 2013)		(Dec 31 2014)

Financial Statements
Kythera Biopharmaceuticals Inc's Assets	$ 195 million	KYTH's Balance sheet
Kythera Biopharmaceuticals Inc's Income	$ -37 million	Quarterly KYTH's Income Statement
KYTH's Income by Division		See KYTH's Income by Division

Annual Return On Assets	(Dec 31 2014) FY 2014	(Dec 31 2013) FY 2013	(Dec 31 2012) FY 2012	FY	FY
Y / Y Total Assets Change	-40.36 %	80.22 %	-	-	-
Total Assets in million	103	173	96	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-136	-52	-37	0	0
Annual Return On Assets	-131.13 %	-29.94 %	-38.24 %	-	-

KYTH's 5 Years Annual ROA >> Back to KYTH Management Effectiveness >> Compare KYTH ROA to its Competitors

More Return On Assets Ratios
KYTH's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KYTH's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KYTH's Competitors
Subscribers only: Roa for Kythera Biopharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for KYTH's Customers

You may also want to know
KYTH's Roi	KYTH's Inventory Turnover Ratio	KYTH's Growth Rates	KYTH's Dividend Comparisons
	KYTH's Profitability Ratios	KYTH's Asset Turnover Ratio	KYTH's Dividend Growth
KYTH's Roe	KYTH's Valuation Ratios	KYTH's Financial Strength Ratios	KYTH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2015, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:07:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.